Search
Arrowhead Pharmaceuticals Inc
ARWRAdd to Watchlist
86.730USD
-0.380-0.44%
Close 08-21 16:00（ET）
12.24BMarket Cap
LossP/E TTM
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-0.44%
5 Days
+0.10%
1 Month
-0.06%
6 Months
+36.22%
Year to Date
+30.64%
1 Year
+306.61%
Key Figures
86.770Open
87.010High
220.65KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.16%Turnover Ratio
87.110Prev. Close
85.500Low
19.08MTurnover
LossP/E Static
26.29P/B
0.00%Div Yield TTM
-14.15%ROA
95.49052wk High
0.21Volume Ratio
-1.63MNet Profit
141.13MShares
-2.2706EPS TTM
1.29Beta
-46.39%ROE
20.44552wk Low
1.73%Amplitude
100.00%Gross Margin
12.24BMarket Cap
6.11Reward/Risk
4.03%Risk Rate
Arrowhead Pharmaceuticals Inc Stock (ARWR) Closed Up by 19.04% on Jul 22: What Signal Does It Send?
• Arrowhead Pharmaceuticals shares rose following positive Phase 3 clinical trial results. • Analysts increased price targets based on successful clinical data and market potential. • Technical indicators currently provide sell signals despite recent positive fundamental developments.
TradingKeyWed, Jul 22
Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 7.27% on Jul 10: What Signal Does It Send?
• Investor sentiment shifted due to pipeline concerns and intensified competition in RNAi therapeutics. • Potential equity dilution and macroeconomic uncertainty are pressuring Arrowhead Pharmaceuticals' near-term stock performance. • Arrowhead reported annual revenue of $829.45 million with a net loss of $1.63 million.
TradingKeyFri, Jul 10
Arrowhead Pharmaceuticals Inc's Score
-0.30vs previous score
Forecast8.57
Financial Health6.98
Technical2.99
Valuation Dimensions9.60
Institutional Confidence7.00
Risk Assessment4.62
Media Coverage
Coverage Level
Very Low
Very High
Positive+
Analyst Rating
Arrowhead Pharmaceuticals Inc Technical Analysis
Technical Indicators
Sell
Summary
Neutral
Moving Average
Neutral
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-1.36/-1.32
Revenue / Forecast
75.25M/54.29M
Arrowhead Pharmaceuticals Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolARWR
Number of employees711
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| BlackRock Institutional Trust Company, N.A. | 13.72% |
| Avoro Capital Advisors LLC | 7.54% |
| Vanguard Portfolio Management, LLC | 5.07% |
| Fidelity Management & Research Company LLC | 4.63% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 42.06% |
| Investment Advisor/Hedge Fund | 29.41% |
| Hedge Fund | 7.57% |
| Individual Investor | 3.76% |
Related Instruments
-0.67%
+1.04%
+0.44%
-0.17%
-1.24%
-0.53%
+1.03%
+0.42%
-0.36%
+0.39%
-0.08%
+0.40%
-0.35%
-1.20%
+1.73%
-0.66%
-2.76%
+0.33%
-4.30%
+1.25%Popular Instruments
FAQs
What is the current price of Arrowhead Pharmaceuticals Inc (ARWR)?
The current price of Arrowhead Pharmaceuticals Inc (ARWR) is 87.11.
What is the symbol of Arrowhead Pharmaceuticals Inc?
The ticker symbol of Arrowhead Pharmaceuticals Inc is ARWR.
What is the 52-week high of Arrowhead Pharmaceuticals Inc?
The 52-week high of Arrowhead Pharmaceuticals Inc is 95.49.
What is the 52-week low of Arrowhead Pharmaceuticals Inc?
The 52-week low of Arrowhead Pharmaceuticals Inc is 20.45.
What is the market capitalization of Arrowhead Pharmaceuticals Inc?
The market capitalization of Arrowhead Pharmaceuticals Inc is 12.30B.
Is Arrowhead Pharmaceuticals Inc (ARWR) currently rated as Buy, Hold, or Sell?
According to analysts, Arrowhead Pharmaceuticals Inc (ARWR) has an overall rating of Buy, with a price target of 110.06.
What is the Earnings Per Share (EPS TTM) of Arrowhead Pharmaceuticals Inc (ARWR)?
The Earnings Per Share (EPS TTM) of Arrowhead Pharmaceuticals Inc (ARWR) is -2.27.